Stock SLNO SOLENO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
40.78 USD -0.92% Intraday chart for Soleno Therapeutics, Inc. -13.25% +1.32%
May. 13 Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating MT
May. 10 Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
AQ
Soleno Therapeutics to Participate in Upcoming Investor Conferences
AQ
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
AQ
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
AQ
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
AQ
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
AQ
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
AQ
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - April 19, 2024
AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
AQ
Soleno Therapeutics : March 2024 Corporate Presentation
PU
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
AQ
Soleno Therapeutics to Present at Upcoming February Investor Conferences
AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLNO Stock
  4. News Soleno Therapeutics, Inc.
  5. Press Releases